Download Nausea and Vomiting

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Stimulant wikipedia , lookup

NK1 receptor antagonist wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Bad Pharma wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Medication wikipedia , lookup

Pharmacognosy wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Prescription costs wikipedia , lookup

Drug interaction wikipedia , lookup

Theralizumab wikipedia , lookup

Dydrogesterone wikipedia , lookup

Neuropharmacology wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Bilastine wikipedia , lookup

5-HT3 antagonist wikipedia , lookup

Psychopharmacology wikipedia , lookup

Transcript
Nausea and
Vomiting
Julia Newell
Jan Siddall 2016
Aims and Objectives
AIM
 To increase your knowledge and confidence in the causes
and
 treatment of nausea and vomiting in palliative care
patients
OBJECTIVES
By the end of the session you will be able to





Describe the various patterns of N+V
Describe the biochemical and physical pathways involved
Consider appropriate investigations/interventions
Be aware of anti-emetics and their receptor activity
Select the appropriate first line antiemetic regime
Background - Why is it
important?






It’s a common and debilitating symptom
Affects up to 70% patients with advanced cancer
There are many mechanisms, patterns and
treatments
It usually a has a single cause
Ranked as a highly distressing symptom, often
more so than pain or breathlessness
An accurate assessment and a good
understanding of the mechanics of nausea and
vomiting is important to guide best effective
treatment
Definitions
Nausea: Unpleasant feeling of need to vomit accompanied
by autonomic symptoms (pallor, cold sweat, salivation,
tachycardia, diarrhoea)
Retching: Rhythmic laboured spasmodic movements of the
diaphragm & abdominal muscles
(usually occurs with nausea and results in vomiting – but not
always)
Vomiting: The forceful propulsion of gastric contents through
the mouth
Regurgitation: Effortless expulsion of foodstuffs – e.g.
oesophageal obstruction
Ask the right questions
 Is
it Nausea? Retching? Vomiting?
 When: did it start? Time(s) of day? Constant/not?
 What: does vomit look like? Amount? Blood?
 How: did it start? How has it been treated so far?
 Why: Exacerbating (& relieving) factors
Why identify cause/s…?
1.
2.
Some causes are treatable and so potentially
reversible
Each antiemetic targets a specific pathway /
‘cause’
Assessment








Distinguish between vomiting, expectoration and
regurgitation
Note contents and volume
Assess relationship between nausea and vomiting
Record severity
Review drug regime (opioids, digoxin etc)
Examine mouth, pharynx and abdomen
Check plasma urea, creatinine, calcium, albumin,
digoxin as appropriate
Examine fundi if raised intracranial pressure
possible
Reason for accurate
assessment
Being able to recognise patterns of N&V
 Identifying likely cause in individual patients
Once this is understood we can plan treatment
by:





Understanding mode of action of commonly
used anti-emetics
Prescribing most appropriate antiemetic
Choosing most appropriate route
Negotiating with patient to ensure compliance
Potential Causes of nausea
and vomiting
Drugs


opioids,
chemotherapy,
digoxin, etc etc etc
Radiotherapy
Especially gut area
Biochemical

Hypercalcaemia,
uraemia
Liver failure
Gastric stasis
Bowel obstruction


Upper/lower
Constipation
Raised intracranial
pressure

Cerebellar
metastases
Anxiety, fear,
conditioned response
5HT3 Antagonists:
Substance P
antagonist:
Drugs:
Ondansetron/Granisitron
Drug:
Aprepitant
Phosaprepitant

chemotherapy/radioth
erapy


Side effects:
Constipation,
headache

prevent acute and
delayed sickness that
can be caused by
chemotherapy
given to patients whose
nausea and vomiting
was severe and was not
controlled by the usual
anti-emetic regimen
Management
Correct the reversible
 Pain, infection, cough, hypercalcaemia, raised ICP,
 constipation, address fears/anxieties
Non drug treatment
 Control malodour e.g from colostomy or fungating wound
 Fresh air.
Good oropharyngeal hygiene.
 Suitable distractions.
 Nurse in the upright position.
 Avoidance of emetogenic smells and foods.
 Avoidance of situations in which N&V is a conditioned
response.
 Drug treatment – depends on pattern and cause…..
Metoclopramide
Pathways:
Peripheral : Prokinetic
- gastric stasis, functional bowel obstruction
Central : Chemoreceptor Trigger Zone (CTZ)
- metabolic induced: ie opioids, hypercalcaemia
 Dose :10mg pre-meal tds PO or 30-120mg Continuous
Subcutaneous Infusion (CSCI)


Side Effects: extrapyramidal, colic, diarrhoea
In renal impairment need dose reduction
NB Domperidone: has same action as metoclopramide
Haloperidol
Pathway:
Central: Chemoreceptor Trigger Zone (CTZ)
- most metabolic causes of vomiting (e.g.
hypercalcaemia, renal failure).


Dose: 0.5 - 10mg PO/CSCI
Long half life
Can be given as a once daily dose at night

Side effects: sedation, extrapyramidal


Cyclizine
Pathway:
Central: vomiting centre - antihistamine and anti muscarinic



Has peripheral antimuscarinic effect which blocks action of
prokinetic drugs ie metoclopramide/domperidone
NB: Drugs with antimuscarinic effects should not be used
concurrently with prokinetic drugs.

Dose: 50mg tds PO/ 150mg CSCI

Side effects: sedation, urine retention, dry mouth,
constipation
NB: Can be skin irritant as S/C injection and not compatible
with all drugs in CSCI
Levomepromazine (Nozinan)
Pathway:
Central: acts at many receptor sites, therefore a broad
spectrum antiemetic
 2nd line: only used if 1st line antiemetics do not work


Dose: 6 – 25mg OD PO, 6.25-25mg CSCI

Side effects: reflect broad spectrum activity –
sedation, constipation, hypotension

NB: has sedative properties, so can be used for
agitation in higher doses
Other Side effects
 IV
Metoclopramide + IV Ondansetron:
may cause serious cardiac arrhythmias
 Metoclopramide/Domperidone +
Cyclizine Metoclopramide/Domperidone
are motility agents while
 Metoclopramide (and others) Oculogyric
crisis Especially in young women
Remember…
Different antiemetics act at different points in the
vomiting mechanism – the drug must be
appropriate to the cause of the nausea and
vomiting.
Always:
identify cause
treat reversible cause
identify emetic pathway which is triggering vomiting
If using > 1 antiemetic:
- combine drugs with different actions
- do not combine drugs which are antagonistic
(blocking)
select antiemetic for identified pathway
Extra-pyramidal side effects







Akathisia
Dystonia
Tardive Dyskinesia
Parkinsonism
Tremor
Rigidity
Bradykinesia
Haloperidol, metoclopramide
(especially high dose) and
levomepromazine can all
cause these.
Non pharmacological
measures
 Rest
 Cold
 Reassurance
 Fresh
air
 Remove
predisposing stimuli
 Oral hygiene
 Small appetising
snacks
lollies
drinks/ice
 Complimentary
therapies:
- acupressure
- behavioural
strategies
Aims and Objectives
 Aims
 Defining
Bowel Obstruction
 Examine the symptoms
 Management Options
 Complications
 Objectives
 An
understanding of bowel obstruction
Other options
Venting Gastrostomy
NG free drainage
Definition of Bowel Obstruction
A
blockage to a section of the bowel,
reducing the motility of the contents of
the gut.
 Can
 Can
be partial or complete
fluctuate between partial and
complete making diagnosis difficult
Cause of Bowel Obstruction
 Anything




which causes an obstruction
Hard faeces
Foreign body
Tumour (internal)
Tumour (pressure on bowel)
Symptoms

Nausea: persistent, fullness

Vomiting: large volume? faeculant?

Abdominal pain

Colic pain: wave like, spasm

Constipation:
- can mimic bowel obstruction
- impaction/overflow
Medical management
 Nausea and vomiting
 If no colic = metoclopramide in syringe driver
 If colic = haloperidol + hyoscine butylbromide
(buscopan) in syringe driver
 Large volume vomits
 hyoscine butylbromide (buscopan)
 octreotide
 Reduction of colic:
 hyoscine butylbromide (buscopan)
Any questions?